Abstract
Surgery, with or without radiation therapy, is the standard of care for primary soft tissue sarcoma, with adjuvant/neodjuvant chemotherapy playing a role only in high-risk patients. Chemotherapy is generally the principal treatment modality for locally advanced or metastatic disease. Within this context, newer techniques and promising new treatments are challenging traditional treatment paradigms. For example, identification of histology-specific treatments is leading the field toward individualized care, with better outcomes. Patients over 65 years represent a sizable and largely undertreated sector of the soft tissue sarcoma population, with many being unsuited to receive anthracycline- or ifosfamide-based chemotherapy. First-line treatment options in this population are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 13-21 |
| Number of pages | 9 |
| Journal | Future Oncology |
| Volume | 13 |
| Issue number | 1s |
| DOIs | |
| Publication status | Published - Jan 1 2017 |
Fingerprint
Keywords
- elderly
- soft tissue sarcoma
- surgical management
- trabectedin
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Treatment of soft tissue sarcoma : A focus on earlier stages. / Gronchi, Alessandro; Maki, Robert G.; Jones, Robin L.
In: Future Oncology, Vol. 13, No. 1s, 01.01.2017, p. 13-21.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of soft tissue sarcoma
T2 - A focus on earlier stages
AU - Gronchi, Alessandro
AU - Maki, Robert G.
AU - Jones, Robin L.
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Surgery, with or without radiation therapy, is the standard of care for primary soft tissue sarcoma, with adjuvant/neodjuvant chemotherapy playing a role only in high-risk patients. Chemotherapy is generally the principal treatment modality for locally advanced or metastatic disease. Within this context, newer techniques and promising new treatments are challenging traditional treatment paradigms. For example, identification of histology-specific treatments is leading the field toward individualized care, with better outcomes. Patients over 65 years represent a sizable and largely undertreated sector of the soft tissue sarcoma population, with many being unsuited to receive anthracycline- or ifosfamide-based chemotherapy. First-line treatment options in this population are discussed.
AB - Surgery, with or without radiation therapy, is the standard of care for primary soft tissue sarcoma, with adjuvant/neodjuvant chemotherapy playing a role only in high-risk patients. Chemotherapy is generally the principal treatment modality for locally advanced or metastatic disease. Within this context, newer techniques and promising new treatments are challenging traditional treatment paradigms. For example, identification of histology-specific treatments is leading the field toward individualized care, with better outcomes. Patients over 65 years represent a sizable and largely undertreated sector of the soft tissue sarcoma population, with many being unsuited to receive anthracycline- or ifosfamide-based chemotherapy. First-line treatment options in this population are discussed.
KW - elderly
KW - soft tissue sarcoma
KW - surgical management
KW - trabectedin
UR - http://www.scopus.com/inward/record.url?scp=85005992400&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85005992400&partnerID=8YFLogxK
U2 - 10.2217/fon-2016-0499
DO - 10.2217/fon-2016-0499
M3 - Article
VL - 13
SP - 13
EP - 21
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 1s
ER -